8-K: Calidi Biotherapeutics Advances Pipeline, Reports Q2 2026 Results

Calidi Biotherapeutics announced positive FDA feedback for CLD-401, advanced its RedTail platform with new data, and reduced G&A expenses in its Q2 2026 report.

Summary

• Calidi Biotherapeutics reported financial results for the second quarter ended June 30, 2026.
• The company received positive pre-IND feedback from the FDA for CLD-401, indicating alignment on development strategy for a first-in-human study targeting Q1 2027.
• New data on CLD-501, utilizing the RedTail platform for in situ delivery of a T-cell engager, was presented at the ASCO Annual Meeting.
• General and administrative expenses were reduced by $1.5 million (48%) in Q2 2026 compared to Q2 2025.
• The company reported a net loss of $4.2 million ($2.94 per share) for Q2 2026, an improvement from a net loss of $5.7 million ($31.75 per share) in Q2 2025, with prior periods adjusted for a reverse stock split.
• Research and development expenses remained stable at $2.6 million.
• Cash and restricted cash totaled $4.3 million as of June 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant progress in clinical development and platform expansion, alongside improved expense management, despite continued net losses.

Positives

• Received positive pre-IND feedback from the U.S. FDA for CLD-401, with agreement on development strategy for a first-in-human study.
• Targeting first patient dosing for CLD-401 in Q1 2027.
• Showcased RedTail platform versatility at ASCO with new CLD-501 data demonstrating simultaneous in situ delivery of a T-cell engager and T-cell amplifier.
• Advancing an EpCam-targeted in situ TCE program, an advancement of the RedTail platform.
• Strengthened Board of Directors with the addition of Corsee Sanders, Ph.D., a former executive from Genentech/Roche and Celgene.
• Reduced general and administrative expenses by $1.5 million, or 48%, in Q2 2026 compared to Q2 2025.
• Net loss per share improved significantly to $(2.94) in Q2 2026 from $(31.75) in Q2 2025 (adjusted for reverse stock split).

Negatives

• The company reported a net loss of $4.2 million for the second quarter of 2026.
• Cash reserves stood at $4.1 million as of June 30, 2026, which may require future capital raises to support ongoing clinical trials.
• Research and development expenses remained unchanged, indicating continued investment without immediate cost reduction in this area.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early results of clinical trials do not necessarily predict final results and that clinical outcomes may change following more comprehensive review or as more patient data becomes available.
• Risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Risk that actual results may differ materially due to timing, cost, and results of R&D activities and preclinical studies.
• Risk related to interactions with and timing/substance of feedback from regulatory authorities.
• Risks associated with manufacturing and supply chain matters.
• Risks related to changes in applicable laws or regulations.
• Risks related to changes in business, market, economic, or competitive conditions.

Future Outlook

The company anticipates CLD-401 entering the clinic during the first quarter of 2027, with first patient dosing targeted for Q1 2027. The company will continue its focus on expense management to ensure sufficient capital to advance its pipeline.

Management Comments

• Throughout the second quarter, Calidi continued to advance its RedTail platform and redefine the potential of oncolytic viruses and genetic medicine.
• We anticipate CLD-401, the lead drug candidate from our RedTail platform, entering the clinic during the first quarter of 2027.
• In addition, we have expanded what the RedTail platform can do with our new approach of in situ T-cell engagers.

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics is operating in the highly competitive and rapidly evolving biotechnology sector, focusing on novel genetic medicines and oncolytic viruses. The positive FDA feedback for CLD-401 and advancements in their RedTail platform, particularly the in situ T-cell engager approach, align with broader industry trends towards more targeted and immunomodulatory cancer therapies.

Comparison to Industry Standards

• The company's net loss of $4.2 million in Q2 2026 is typical for early-stage biotechnology firms investing heavily in R&D, though the reduction in G&A expenses by 48% is a positive operational efficiency measure.
• Advancing a lead candidate like CLD-401 towards a first-in-human study in Q1 2027 is a key milestone, comparable to other companies in the oncology therapeutic development space.
• The development of in situ T-cell engagers (TCEs) represents an innovative approach, positioning Calidi alongside other biotechs exploring advanced immunotherapy strategies, though specific comparable company data for this exact modality is still emerging.

Management Changes

Related Party Transactions

• Related party accounts payable of $18.
• Related party accrued expenses and other current liabilities of $530.
• Related party warrant liability of $5.
• Interest expense related party of $6 for the three months ended June 30, 2026.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical development milestones are met, but also risk associated with continued losses and potential need for capital raises.
• Employees: Continued focus on expense management may impact hiring or resource allocation.
• Creditors: The company's cash position and ongoing losses present a risk to creditors if future funding is not secured.

Next Steps

• Advance CLD-401 towards a first-in-human study.
• Initiate first patient dosing for CLD-401 in Q1 2027.
• Continue advancing the EpCam-targeted in situ TCE program.
• Continue to manage expenses to ensure sufficient capital for pipeline advancement.

Key Dates

Recommendation

The company shows promising clinical development progress and platform innovation, with positive FDA feedback and reduced operating expenses. However, the continued net losses and the inherent risks in drug development, including the need for future capital, warrant a 'hold' recommendation until further clinical data and funding clarity emerge.

Keywords

biotechnology, genetic medicines, oncolytic viruses, RedTail platform, CLD-401, CLD-501, T-cell engager, FDA